Dr Amy Pearlman, M.D., a board-certified urologist and nationally recognised leader in sexual medicine, has joined the LTR Pharma’s Scientific Advisory Board.
Dr Pearlman is Co-founder of Prime Institute in Florida and a fellowship-trained specialist in male sexual and hormonal health. She is a former Director of the Men’s Health Program at the University of Iowa, serves on the editorial board of Urology Times, and has contributed to the Fifth International Consultation on Sexual Medicine (ICSM 2024).
Her appointment supports LTR Pharma’s planned US launch of ROXUS® in H1 CY2026 and strengthens our clinical and market access capabilities for SPONTAN® and ROXUS® – our rapid-onset nasal spray treatments for erectile dysfunction.
Dr Amy Pearlman, said:
“I believe SPONTAN and ROXUS will be important additions to treatment options in the United States for men seeking effective, rapid-onset erectile dysfunction treatment. The intranasal delivery platform offers a compelling alternative to current oral medications, providing onset of action in 10 minutes or less with an excellent safety profile. Having dedicated my career to advancing sexual health and wellness, I’m thrilled to join LTR Pharma’s Scientific Advisory Board and contribute to bringing these innovative treatments to American patients who deserve better options for spontaneous intimacy.”